Riskpilot← Back to searchSign inGet full accessBioinnovate Global AB
ABActiveOrg 5591006845Bryggaregatan 17 DResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20171 employees
Revenue 2024
SEK 1,2M
-49% vs 2023
EBITDA margin
53.7%
-63% vs 2023
Equity ratio
53.2%
Financial strength
Net profit 2024
SEK 389K
-63% vs 2023
| Revenue | SEK 1,2M | -49% |
| EBITDA | SEK 648K | -63% |
| Net profit | SEK 389K | -63% |
| Total assets | SEK 2,6M | +22% |
| Equity | SEK 1,4M | +16% |
| Employees | 1 | — |
Legal name
Bioinnovate Global AB
Org number
5591006845
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 februari 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget skall bedriva rådgivning inom skolväsendet, samt bidra med ekologiska innovationer inom den gröna sektorn och folkhälsan, och idka därmed förenlig verksamhet.
Address
Bryggaregatan 17 D
Email
info@bioinnovate.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 391 | 312 | 363 | 2 387 | 1 206 |
| Staff expenses | — | — | −43 | −44 | −54 |
| EBITDA | 241 | 82 | 80 | 1 730 | 648 |
| Depreciation & amort. | −7 | −0 | — | — | — |
| EBIT | 234 | 82 | 80 | 1 730 | 648 |
| Net financials | — | — | −0 | 4 | 26 |
| Profit before tax | 176 | 62 | 60 | 1 324 | 499 |
| Tax | −38 | −13 | −12 | −273 | −110 |
| Net profit | 138 | 49 | 47 | 1 051 | 389 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 458 | 538 | 409 | 2 153 | 2 629 |
| Equity | 284 | 333 | 260 | 1 211 | 1 399 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 96 | 108 | 31 | 414 | 527 |
| Total debt | 96 | 108 | 31 | 414 | 527 |
EBITDA margin
53.7%
This company
15.8%
Market median
+240% vs market
20202024
Equity ratio
53.2%
This company
38.2%
Market median
+39% vs market
20202024
Return on equity
27.8%
This company
18.4%
Market median
+51% vs market
20202024
Net profit margin
32.2%
This company
8.1%
Market median
+298% vs market
20202024
Asset turnover
0.46×
This company
1.12×
Market median
-59% vs market
20202024
Debt / equity
0.88×
This company
0.62×
Market median
+42% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AR Authorized Recipient of Service | Authorized Recipient of Service | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bioinnovate Global AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anja Ragnhild Charlotta Hellmark | Authorized Recipient of Service | 0 companies |
| Teunis Dekker | Board of Directors | 0 companies |
| Melani Sabine Moniharapon | Deputy Board Member | 0 companies |